Baxter floats $500M note issue; Glaxo sues Glenmark over malaria med;

> Baxter International sold $500 million worth of notes with a 4.5 percent coupon and maturity in 2019. Report [1]

> GlaxoSmithKline sued Glenmark Generics, alleging infringement of three U.S. patents on its malaria remedy Maladone. Report [2]

> Amerisource Bergen promoted Steven Collins, head of its specialty drug division, to executive vice president of the company's largest subsidiary, Amerisource Drug Corp. Report [3]

> Shares of Vasogen rose more than 10 percent Monday after the Canadian biotech agreed to be taken over by IntelliPharmaCeutics, a closely held manufacturer of controlled release drugs. Report [4]

> Labopharm and Biovail stocks suffered on a court ruling that cleared the way for Par Pharmaceuticals to launch its version of tramadol hydrochloride, which Labopharm manufactures as Ryzolt and Biovail sells under the name Ultram ER. Report [5]

> Protalix BioTherapeutics said the FDA approved a treatment protocol for its experimental drug for Gaucher disease, sending its shares soaring 30 percent. Report [6]

> Abbott Laboratories is expanding its post-approval study for the Xience V stent system by 3,000, up from the initial enrollment of 5,000. Report [7]

Biotech News

> With its profits sliding, the big CRO Covance has put plans for a $145 million campus in Prince William County, VA on hold for up to two years. Report [8]

> Denmark's NeuroSearch has snared a development pact with J&J's Janssen Pharmaceutica that comes with about $46 million in guaranteed payments. Under the deal, NeuroSearch will help advance and commercialize new drugs for the central nervous system. Report [9]

> Shares of AEterna Zentaris went into meltdown mode after the developer announced that a closely watched Phase III trial of the benign prostatic hyperplasia drug cetrorelix had failed to hit its primary endpoint. Report [10]

> Shares of Protalix BioTherapeutics shot up 30 percent this morning after the developer announced that the FDA had approved the interim use of its experimental therapy for Gaucher's disease. Report [11]

> Repros Therapeutics revealed that its cash reserves are running out and that it will have to either file for bankruptcy or dissolve the company if it can't quickly lay its hands on some operating cash. Report [12]

Research News

> While Massachusetts and California have been gaining wide recognition for cutting-edge scientific work in the stem cell field, Cleveland has been quietly building up its own reputation in the burgeoning new industry. Report [13]

> Over the past several years there's been a growing amount of research to prove that caloric restriction can trigger longer life spans. And the potential to use drugs to trigger the same biologic pathways that can extend life has inspired a biotech company to take its therapeutic approach into the clinic. Report [14]

> Scientists at Stanford found a surprising link between high blood pressure and multiple sclerosis that could quickly pave the way to an inexpensive new approach to treating the disease. Report [15]

> An inch-long marine worm has inspired researchers to develop a new adhesive that can be used to repair shattered bones. Report [16]

And Finallly... A centuries-old Chinese herbal remedy helped relieve joint pain and inflammation in patients with rheumatoid arthritis, a U.S. study showed. Report [7]